A recent phase III study shows that the combination of azacitidine with the IDH1 inhibitor ivosidenib is more effective than azacitidine alone in patients with acute myeloid leukemia who aren't eligible for intensive chemotherapy. The drug duo tripled overall survival and increased complete remission and event-free survival rates.

You do not currently have access to this content.